{"id":"NCT01463306","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","briefTitle":"A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures","officialTitle":"A 12-MONTH OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PREGABALIN AS ADJUNCTIVE THERAPY IN PEDIATRIC SUBJECTS 1 MONTH TO 16 YEARS OF AGE WITH PARTIAL ONSET SEIZURES AND PEDIATRIC AND ADULT SUBJECTS 5 TO 65 YEARS OF AGE WITH PRIMARY GENERALIZED TONIC-CLONIC SEIZURES","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-02-21","primaryCompletion":"2019-08-22","completion":"2019-08-22","firstPosted":"2011-11-01","resultsPosted":"2020-02-21","lastUpdate":"2021-01-20"},"enrollment":605,"design":{"allocation":"NA","model":null,"masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Epilepsy, Partial Seizures","Epilepsy, Primary Generalized Tonic-Clonic Seizures"],"interventions":[{"type":"DRUG","name":"Pregabalin","otherNames":["Lyrica"]}],"arms":[{"label":"Open","type":"EXPERIMENTAL"}],"summary":"Study A0081106 is a 12-month open-label study to evaluate the long term safety and tolerability of pregabalin as add-on therapy in pediatric subjects 1 month to 16 years of age with partial onset seizures and pediatric and adult subjects 5 to 65 years of age with primary generalized tonic-clonic seizures. Pregabalin will be administered in equally divided daily doses for 1 year, in either capsule or liquid oral formulation.","primaryOutcome":{"measure":"Number of Participants With Treatment Emergent Adverse Events (AEs), Treatment Emergent Serious Adverse Events (SAEs), Treatment Related AEs and Treatment Related SAEs","timeFrame":"Baseline (Day 1) up to 13 Months","effectByArm":[{"arm":"Pregabalin: Previous and Current","deltaMin":252,"sd":null},{"arm":"Placebo-Previous to Pregabalin-Current","deltaMin":140,"sd":null},{"arm":"Direct Pregabalin","deltaMin":10,"sd":null}],"pValues":[]},"eligibility":{"minAge":"1 Month","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":151,"countries":["United States","Belarus","Belgium","Bosnia and Herzegovina","Bulgaria","China","Czechia","France","Germany","Greece","Hungary","India","Israel","Italy","Lebanon","Malaysia","Montenegro","Philippines","Poland","Romania","Russia","Serbia","Singapore","Slovakia","South Korea","Spain","Taiwan","Thailand","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":[],"seeAlso":["https://trialinfoemail.pfizer.com/pility%20Of%20Pregabages/landing.aspx?StudyID=A0081106"]},"adverseEventsSummary":{"seriousAny":{"events":53,"n":384},"commonTop":["Upper respiratory tract infection","Pyrexia","Somnolence","Weight increased","Nasopharyngitis"]}}